Physician profile
Derek Alan Lapp
NPI 1679936819
$2,470.66
in general payments reported to CMS, 2019-2025
27 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.93 · 2022: $723 · 2023: $716 · 2024: $718 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.72 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $399.67 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $377.29 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $319.72 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $159.72 | 2022 | |
| Tandem Diabetes Care, INC. | $114.92 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.06 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $98.72 | 2022-2024 | Evenity, Prolia, Tepezza |
| Antares Pharma, INC. | $96.73 | 2021-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $95.07 | 2022-2023 | |
| Amryt Pharma Holdings LTD | $93.27 | 2022-2023 | Mycapssa |
| Amneal Pharmaceuticals LLC | $83.80 | 2023-2025 | Unithroid |
| Insulet Corporation | $65.06 | 2022-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $62.76 | 2022-2025 | Gvoke Hypopen |
| Medtronic, INC. | $57.51 | 2022-2025 | Minimed 780g |
| Abbott Laboratories | $56.81 | 2024-2025 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49.58 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $43.41 | 2024-2025 | |
| Corcept Therapeutics | $36.43 | 2023 | Korlym |
| Verity Pharmaceuticals INC. | $23.07 | 2025 | Tlando |
| Neurocrine Biosciences, INC. | $22.24 | 2024 | |
| Cequr Corporation | $18.06 | 2022-2023 | Cequr Simplicity |
| Pfizer INC. | $17.15 | 2024 | |
| Zealand Pharma US, INC. | $17.05 | 2022 | |
| Beta Bionics, INC. | $16.86 | 2023 | Ilet Bionic Pancreas |
| Alexion Pharmaceuticals, INC. | $15.58 | 2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $14.39 | 2022 | |
| Horizon Therapeutics Plc | $13.73 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Lapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.